Left Atrium: A New Prognostic Marker and Therapeutic Target in Secondary Mitral Regurgitation?-Reference-Cited by-同舟云学术

Left Atrium: A New Prognostic Marker and Therapeutic Target in Secondary Mitral Regurgitation?

Published:2024-05-14 Issue: Volume:19 Page:
ISSN:1758-3764
Container-title:European Cardiology Review
language:en
Short-container-title:Eur Cardiol

Author:

Koukos Markos¹^ORCID,Dimitroglou Yannis¹^ORCID,Tsartsalis Dimitrios¹^ORCID,Beneki Eirini¹^ORCID,Tolis Elias¹^ORCID,Patsourakos Dimitrios¹^ORCID,Kalompatsou Argyro¹^ORCID,Aggeli Constantina¹^ORCID,Tsioufis Konstantinos¹^ORCID

Affiliation:

1. 1st Department of Cardiology, Hippokration Hospital of Athens, University of Athens, Athens, Greece

Abstract

Mitral regurgitation (MR) is one of the most common valvular abnormalities worldwide and can be subdivided into primary and secondary causes. Atrial MR consists of a novel type of secondary MR (SMR), most often observed in patients with AF and heart failure with preserved ejection fraction. The main pathophysiological mechanism of atrial MR is mitral valve annular dilatation. Recently published studies have highlighted the clinical significance of left atrium (LA) evaluation in the early diagnosis and prognosis of patients with primary MR. However, there are little data regarding the role of the LA in SMR. The present literature review aims to elucidate the use of the echocardiographic parameters regarding LA evaluation in the prognosis prediction and therapeutic strategy of patients with SMR.

Publisher

Radcliffe Media Media Ltd

Reference57 articles.

1. Aluru JS, Barsouk A, Saginala K, et al. Valvular heart disease epidemiology. Med Sci (Basel) 2022;10:32. https://doi.org/10.3390/medsci10020032; PMID: 35736352.

2. Lancellotti P, Pibarot P, Chambers J, et al. Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging 2022;23:e171–232. https://doi.org/10.1093/ehjci/jeab253; PMID: 35292799.

3. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395.

4. Dziadzko V, Dziadzko M, Medina-Inojosa JR, et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. Eur Heart J. 2019;40:2194–2202. https://doi.org/10.1093/eurheartj/ehz314. PMID: 31121021.

5. Huang AL, Dal-Bianco JP, Levine RA, Hung JW. Secondary mitral regurgitation: cardiac remodeling, diagnosis, and management. Struct Heart 2023;7:100129. https://doi.org/10.1016/j.shj.2022.100129; PMID: 37273859.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial Functional Mitral Regurgitation: From Diagnosis to Current Interventional Therapies;Journal of Clinical Medicine;2024-08-25